Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05862285 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05862285 · ClinicalTrials.gov record · last posted 2026-08-10

A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study

Study acronym: UmbrellaMAX
StatusRecruiting
PhasePhase 3
Started2023-06-01
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this extension study is to provide continued treatment with Roche investigational medicinal product (IMP\[s\]) monotherapy or Roche IMP(s) combined with other agent(s) or comparator agent(s) for eligible participants with cancer who are still on study treatment at the time of roll-over from the parent study and who do not have access to the study treatment locally.

Protocol amendment history 2 changes detected by DataLookout

2026-07-11
Trial sites expanded: 62 → 67 locations
2026-06-13
Trial sites expanded: 58 → 62 locations
Trial Details
NCT Number NCT05862285
Lead Sponsor Hoffmann-La Roche
Conditions Cancer
Enrollment 100 participants
Start Date 2023-06-01
Primary Completion 2033-03-01 (estimated)
Study Completion 2033-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-10